Oral Verapamil Tested in Newly Diagnosed Children With Type 1 Diabetes
Tests oral verapamil against placebo in children and teens newly diagnosed with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Oral Verapamil Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 18 years old?
Source: NCT07804849, who can take part
Where in Egypt
- Ain Shams UniversityCairo, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ain Shams University
- Trial code
- NCT07804849
- Record updated
- 4 September 2026
- Original description
Type 1 diabetes (T1D) in children involves autoimmune destruction of pancreatic ß- cells, leading to insulin deficiency. Verapamil is an L-type calcium channel blocker that has been used for decades to treat hypertension and certain cardiac conditions. Recent research has revealed its potential as a ß- cell-protective agent. Hence this study will evaluate the effect of once-daily oral verapamil on pancreatic ß- cell reserve , glycemic metrics and daily insulin requirements in children and adolescents with T1D.Read full original descriptionShow less
Efficay and Safety of Oral Verapamil on Glycemic Metrics and ß-cell Reserve Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes
Type 1 diabetes (T1D) in children involves autoimmune destruction of pancreatic ß- cells, leading to insulin deficiency. Verapamil is an L-type calcium channel blocker that has been used for decades to treat hypertension and certain cardiac conditions. Recent research has revealed its potential as a ß- cell-protective agent. Hence this study will evaluate the effect of once-daily oral verapamil on pancreatic ß- cell reserve , glycemic metrics and daily insulin requirements in children and adolescents with T1D.
Inclusion: Children and adolescents aged 10-18 years; Newly diagnosed type 1 diabetes mellitus (within 6 weeks of diagnosis, defined as the day of starting insulin therapy); Presence of at least two positive islet autoantibody (anti glutamic acid decarboxylase antibodies, anti- tyrosine phosphataseantibodies ,anti- zinc transporter 8 protein antibodies , or anti-insulin antibodies); Ability to comply with study procedures.
Exclusion: Previous diagnosis of other endocrine disorders or autoimmune disorder (e.g. autoimmune thyroiditis); Known allergy or intolerance to verapamil; Cardiac conduction abnormalities, heart block, or significant cardiac disease; Severe hepatic or renal impairment; Current or planned use of medications that might affect glucose metabolism (e.g., corticosteroids, immunomodulators); Systolic or diastolic blood pressure < 5th percentile for age and gender; Participation in another interventional clinical trial; Inability to follow the protocol for any reason as determined by the investigator; Elevated liver enzymes >1.5 × upper limit of normal at screening.